Partner at Deerfield Management · Joined 2013
View Live Interactive Profile →Jonathan Leff is a Partner on Deerfield's Therapeutics team and joined the firm in 2013, focusing on venture capital and structured investments in biotechnology and pharmaceuticals. Before Deerfield he was with Warburg Pincus, where he led the firm's investment efforts in biotechnology and pharmaceuticals; Larimar Therapeutics' 2026 proxy statement describes him as a Managing Director at Warburg Pincus from 2000 to 2012, while Deerfield's own profile says he was there for more than sixteen years. Larimar Therapeutics' DEF 14A filed 20 April 2026 states that he has served on its board since May 2020, is a Class I director with a term expiring in 2027, chairs the Compensation, Nominating and Corporate Governance Committee, and describes him as a partner at Deerfield Management Company, L.P. and Chairman of the Deerfield Institute. He resigned from the board of BiomX Inc. effective 9 February 2026. He sits on not-for-profit boards including the Spinal Muscular Atrophy Foundation and the Columbia University Medical Center Board of Advisors, previously served as a director of the Reagan-Udall Foundation for the Food and Drug Administration, previously served on the Executive Committee of the Board of the National Venture Capital Association as Chair of its Medical Innovation and Competitiveness Coalition, and previously served on the Board of the Biotechnology Innovation Organization. He holds an A.B. from Harvard University, an M.B.A. from Stanford University's Graduate School of Business and an M.S. in Biotechnology from Johns Hopkins University.